Article

Dynamic Interplay of miR-155-5p Transfer in the Mechanisms Underlying Ibrutinib Resistance in DLBCL through Extracellular Vesicles

2024-03-05

Abstract excerpt

Ibrutinib, a Bruton Tyrosine Kinase (BTK) inhibitor, has exhibited efficacy in various B-cell lymphoid malignancies. However, prolonged usage may lead to resistance, impacting treatment outcomes. The oncogenic microRNA, miR-155-5p is related with poor prognosis in B-cell lymphomas, prompting our investigation into the mechanism of acquired ibrutinib resistance in B-cell lymphoma cells. To generate ibrutinib-resist...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: da62a93f-bb51-54c6-95ab-5aa86ad13416
DOI: 10.21203/rs.3.rs-3951865/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Dynamic Interplay of miR-155-5p Transfer in the Mechanisms Underlying Ibrutinib Resistance in DLBCL through Extracellular VesiclesDOI 10.21203/rs.3.rs-3951865/v1Read

MicroRNA-155 controls vincristine sensitivity and predicts superior clinical outcome in diffuse large B-cell lymphomaSemantic proximity Read

Ibrutinib in Chronic Lymphocytic Leukemia: Clinical Applications, Drug Resistance, and ProspectsSemantic proximity Read

The Role of microRNA-155 as a Biomarker in Diffuse Large B-Cell LymphomaSemantic proximity Read

MicroRNAs in lymphoma, from diagnosis to targeted therapySemantic proximity Read

IL-16 production is a mechanism of resistance to BTK inhibitors and R-CHOP in lymphomasSemantic proximity Read

Cyclin-Dependent Kinase 5 Contributes to Bruton’s Tyrosine Kinase Inhibitor Resistance via the IRE1α/XBP1 Axis in Mantle Cell LymphomaSemantic proximity Read

Distinct BTK inhibitors differentially induce apoptosis but similarly suppress chemotaxis and lipid accumulation in mantle cell lymphomaSemantic proximity Read

Discovery and biological evaluation of a potent small molecule CRM1 inhibitor for its selective ablation of extranodal NK/T cell lymphomaSemantic proximity Read

Dissection of subclonal evolution by temporal mutation profiling in chronic lymphocytic leukemia patients treated with ibrutinibSemantic proximity Read

Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in Preclinical ModelsSemantic proximity Read

miR-28 plus ibrutinib as a novel combination therapy for Diffuse Large B Cell LymphomaSemantic proximity Read

Exosomes Derived from Burkitt’s Lymphoma Cell Lines Induce Proliferation, Differentiation, and Class-Switch Recombination in B CellsSemantic proximity Read